HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Top Cited Papers
- 13 March 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 23 (4), 517-525
- https://doi.org/10.1038/nm.4292
Abstract
HRDetect represents a model integrating whole-genome sequencing mutation signatures associated with BRCA1 and BRCA2 deficiency. The implementation of this predictor across different tumor types identifies a larger proportion of patients displaying ‘BRCAness’ than previously recognized; they might derive benefit from platinum and PARP-inhibitor therapies. Approximately 1–5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic substitution, insertion/deletion and rearrangement patterns, or 'mutational signatures', were associated with BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency. A weighted model called HRDetect was developed to accurately detect BRCA1/BRCA2-deficient samples. HRDetect identifies BRCA1/BRCA2-deficient tumors with 98.7% sensitivity (area under the curve (AUC) = 0.98). Application of this model in a cohort of 560 individuals with breast cancer, of whom 22 were known to carry a germline BRCA1 or BRCA2 mutation, allowed us to identify an additional 22 tumors with somatic loss of BRCA1 or BRCA2 and 47 tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected. We validated HRDetect on independent cohorts of breast, ovarian and pancreatic cancers and demonstrated its efficacy in alternative sequencing strategies. Integrating all of the classes of mutational signatures thus reveals a larger proportion of individuals with breast cancer harboring BRCA1/BRCA2 deficiency (up to 22%) than hitherto appreciated (∼1–5%) who could have selective therapeutic sensitivity to PARP inhibition.Keywords
This publication has 51 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor ProfilingPLOS ONE, 2013
- Deciphering Signatures of Mutational Processes Operative in Human CancerCell Reports, 2013
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- The Life History of 21 Breast CancersCell, 2012
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsAnnals of Oncology, 2010
- Allele-specific copy number analysis of tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Accurate whole human genome sequencing using reversible terminator chemistryNature, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008